Following FDA OK for MDx System, C. Diff Test, Qiagen to Rapidly Expand Test Menu to Drive Growth | GenomeWeb

NEW YORK (GenomeWeb) — Qiagen has achieved a major milestone in its efforts to expand uptake of its QIAsymphony RGQ molecular diagnostics system, as the company disclosed this week that the platform recently received 510(k) clearance from the US Food and Drug Administration.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.